Andrea Gazzo

May 1, 2024 | biorxiv.org | Avantika Gupta |Andrea Gazzo |Pier Selenica |Anton Safonov

AbstractAcquired genetic alterations commonly drive resistance to endocrine and targeted therapies in metastatic breast cancer, however the underlying processes engendering these diverse alterations are largely uncharacterized. To identify the mutational processes operant in breast cancer and their impact on clinical outcomes, we utilized a well-annotated cohort of 3,880 patient samples with paired tumor-normal sequencing data.